Per joined Ferring Pharmaceuticals in 2015 and was appointed President on January 1st, 2019. Privately-owned, Ferring is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. The company is a leader in reproductive medicine and maternal health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth.

Per previously held executive and senior leadership positions in research, medical and clinical development at Novo Nordisk and AstraZeneca. 

Before joining the pharmaceutical industry, he held the position of Associate Professor at the Karolinska Institute, Sweden, and Washington University School of Medicine, USA.

Per has an M.D. degree and a Ph.D. in Biochemistry and Clinical Chemistry from Gothenburg University, Sweden.